cbst

PropThink: Big Catalysts Approaching For Trius Therapeutics

[ACN Newswire] – By Jason Napodano, CFAFundamentals at Trius Therapeutics (NASDAQ:TSRX) remain solid. I see the development of tedizolid, current in its second phase 3 trial, as low risk. Data from the first phase 3 trial … moreView todays social media effects on CBSTView the latest stocks trending across Twitter. Click to view dashboard […]

November 8, 2012 Bystocknews cbst, stock Comments Off read more

PropThink: Lower Dificid Price Doesn’t Resonate With Analysts; OPTR Could Trade Lower

[ACN Newswire] – By David MoskowitzYesterday, Optimer Pharmaceuticals (NASDAQ:OPTR) hosted its Analyst Day, describing a new lower pricing policy with hospitals to spur demand of Dificid. Our negative view of the meeting … moreView todays social media effects on CBSTView the latest stocks trending across Twitter. Click to view dashboard […]

October 9, 2012 Bystocknews cbst, stock Comments Off read more